PRIMECAP MANAGEMENT CO/CA/PRIMECAP MANAGEMENT CO/CA/

Institutional investor · Portfolio as of Q1 2023

Top Holdings331 positions

Checking export access…
Activity:

Eli Lilly and Company

25.4M$8.7B7.6%$104.89+219.22%
18 qtrssince 2018-Q4
Decreased
0

BIOGEN INC

16M$4.4B3.9%$298.86-6.97%
18 qtrssince 2018-Q4
Increased
60

Amgen Inc.

15.1M$3.7B3.2%$154.26+40.77%
18 qtrssince 2018-Q4
Decreased
0

Microsoft Corporation

11.4M$3.3B2.9%$94.43+197.02%
18 qtrssince 2018-Q4
Decreased
0
AZNAZN
ADR

ASTRAZENECA PLC

45.4M$3.2B2.7%$64.10+104.08%
18 qtrssince 2018-Q4
Increased
55

FEDEX CORP

13.6M$3.1B2.7%$117.29+46.26%
18 qtrssince 2018-Q4
Decreased
0

Texas Instruments Incorporated

16.6M$3.1B2.7%$76.19+120.80%
18 qtrssince 2018-Q4
Decreased
0

KLA Corporation

6.3M$2.5B2.2%$8.13+376.76%
18 qtrssince 2018-Q4
Decreased
0

Adobe Inc.

6.3M$2.4B2.1%$226.24+70.34%
18 qtrssince 2018-Q4
Decreased
0

MICRON TECHNOLOGY INC

38.9M$2.4B2.0%$30.94+92.07%
18 qtrssince 2018-Q4
Decreased
0

Intel Corporation

69.1M$2.3B2.0%$38.83-17.88%
18 qtrssince 2018-Q4
Increased
61
SONYSONY
ADR

SONY GROUP CORP

24M$2.2B1.9%$9.26+93.25%
18 qtrssince 2018-Q4
Decreased
0

Alphabet Inc.

20.8M$2.2B1.9%$52.04+97.46%
18 qtrssince 2018-Q4
Decreased
0

Thermo Fisher Scientific Inc.

3.6M$2.1B1.8%$222.42+156.29%
18 qtrssince 2018-Q4
Decreased
0

Tesla, Inc.

9.9M$2B1.8%$19.31+974.28%
18 qtrssince 2018-Q4
Decreased
0

Boston Scientific Corporation

38.3M$1.9B1.7%$35.74+40.00%
18 qtrssince 2018-Q4
Increased
51

BIOMARIN PHARMACEUTICAL INC

18.2M$1.8B1.5%$84.68+14.84%
18 qtrssince 2018-Q4
Increased
52

Wells Fargo & Company

47.4M$1.8B1.5%$36.98-7.46%
18 qtrssince 2018-Q4
Decreased
0
BABABABA
ADR

ALIBABA GROUP HLDG LTD

17.3M$1.8B1.5%$144.16-33.30%
18 qtrssince 2018-Q4
Increased
50

SOUTHWEST AIRLS CO

50.9M$1.7B1.4%$41.74-27.67%
18 qtrssince 2018-Q4
Decreased
0
$114.7B
AUM
331
Positions
Q1 2023
Filing
HI score · 3.0/5
Quarterly 13F Value Change
+2%Q4'21$144.5B-8%Q1'22$132.6B-16%Q2'22$111.9B-8%Q3'22$103.3B+6%Q4'22$109.2B+5%Q1'23$114.7B
Activity profile
$ moved · Q1'23
New2%Increased29%Decreased68%Exited1%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.3 years
<1Q3%1-4Q5%1-2Y10%2Y+82%

PRIMECAP MANAGEMENT CO/CA/ manages $114.7B across 331 positions as of Q1 2023. Top holdings: LLY (7.6%), BIIB (3.9%), AMGN (3.2%). Fund DNA: Steady Compounder. HoldingsIntel Score: 3/5.0.

Q1 2023 Summary

Active quarter - 10 new positions, 13 exits, 89 increased. Top move: INTC (INCREASED, conviction 61). Portfolio: $114.7B across 331 positions.

Top holdings by portfolio weight

Total AUM$115B
LLY7.60%
BIIB3.88%
AMGN3.19%
MSFT2.88%
AZN2.75%
FDX2.70%
TXN2.70%
KLAC2.21%
ADBE2.11%
MU2.05%
Other1.97%

Portfolio allocation by GICS sector

Sectors11
Healthcare30.83%
Technology27.91%
Industrials11.96%
Consumer Cyclical9.20%
Financial Services7.42%
Communication Services5.67%
Unknown4.60%
Basic Materials0.98%
Energy0.85%
Consumer Defensive0.55%
Other0.02%

Behavioral investing profile

Checking access…
Steady Compounder- primarily Healthcare, Technology, Industrials
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(3.0 / 5.0)
Holdings P&L69
Conviction36
Concentration64
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
COPCOPConocoPhillips
Q4 2024 → Q2 2026+7.3M shares+$749.8M
7Q
SCHWSCHWCharles Schwab Corp
Q4 2024 → Q2 2026+24.1M shares+$2.3B
7Q
USFDUSFDUS FOODS HLDG CORP
Q4 2024 → Q2 2026+3.7M shares+$389.3M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used